Institutional members access full text with Ovid®

Share this article on:

Prolonged Survival After Treatment of Diffuse Intrinsic Pontine Glioma with Radiation, Temozolamide, and Bevacizumab: Report of 2 Cases

Aguilera, Dolly G. MD; Mazewski, Claire MD; Hayes, Laura MD; Jordan, Cathy CPNP; Esiashivilli, Natia MD; Janns, Anna MD, PhD; MacDonald, Tobey J. MD

Journal of Pediatric Hematology/Oncology: January 2013 - Volume 35 - Issue 1 - p e42–e46
doi: 10.1097/MPH.0b013e318279aed8
Online Articles: Clinical and Laboratory Observations

Background: Diffuse intrinsic pontine gliomas have poor prognosis.

Observation: We report on 2 patients with diffuse intrinsic pontine glioma treated with radiation, followed by temozolamide 200 mg/m2/d for 5 days every 28 days and bevacizumab 10 mg/kg/dose every 14 days. Both patients have ongoing PFS of 37 and 47 months from diagnosis. A decrease in tumor size by >65% was observed in both the patients. Both patients continue treatment. No steroid requirement since 10 weeks after radiation. Quality of life is excellent and the chemotherapy regimen is well tolerated.

Conclusions: A clinical trial in an expanded cohort is warranted to determine the toxicity and evaluate response.

*Aflac Center for Cancer and Blood Disorders Service, Children’s Healthcare of Atlanta, Emory University School of Medicine

Department of Radiology, Children’s Healthcare of Atlanta

Department of Radiation Oncology, Winship Cancer Center Institute of Emory University, Atlanta, GA

The authors declare no conflict of interest.

Reprints: Tobey J. MacDonald, MD, Aflac Center for Cancer and Blood Disorders Service, Children’s Healthcare of Atlanta, Emory University School of Medicine, 2015 Uppergate Drive, #442, Atlanta, GA 30322 (e-mail: tobey.macdonald@emory.edu).

Received September 6, 2011

Accepted July 13, 2012

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.